Battle Against Prostate, Bladder Cancer: License Deal Signals Major Breakthrough

“A new license announced will bring to market a new test that will help with the early detection of prostate and bladder cancers. Scientists have developed a more reliable way of detecting prostate and bladder cancers, by testing a small urine sample. The team focused on the EN2 protein produced by these types of cancers, and which is secreted into urine. Clinical trials in both Europe and the United States have found that the EN2 biomarker test is twice as effective as the 30-year-old PSA blood test currently used to detect prostate cancer.”

Role of Engrailed-2 (EN2) as a Prostate Cancer Detection Biomarker in Genetically High Risk Men

“Controversy surrounds the use of PSA as a biomarker for prostate cancer detection, leaving an unmet need for a novel biomarker in this setting; urinary EN2 may identify individuals with clinically relevant prostate cancer. Male BRCA1 and BRCA2 mutation carriers are at increased risk of clinically significant prostate cancer and may benefit from screening. Urine samples from 413 BRCA1 and BRCA2 mutation carriers and controls were evaluated. Subjects underwent annual PSA screening with diagnostic biopsy triggered by PSA > 3.0 ng/ml; 21 men were diagnosed with prostate cancer. Urinary EN2 levels were measured by ELISA and had a sensitivity of 66.7% and specificity of 89.3% for cancer detection. There was no statistically significant difference in EN2 levels according to genetic status or Gleason score. Urinary EN2 may be useful as a non-invasive early biomarker for prostate cancer detection in genetically high-risk individuals.”